NCT04582539: Phase 1/2: Safety and Tolerability of INCB000928 in Myelodysplastic Synd. or Myeloma

• NCT04582539: Phase 1/2: To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma.

NCT04582539: Phase 1/2: To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma.

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.

Sponsor

Incyte Corporation

---

ClinicalTrials.gov Identifier: NCT04582539

Official Title: A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma

First Posted : October 9, 2020

Click here to see details on ClinicalTrials.gov

---

Drug: INCB000928

---

INCB000928

ALK2 Inhibitor INCB000928 (Code C175551)

ALK2 Inhibitor INCB000928

INCB 000928

INCB-000928

INCB000928

---

Locations

United States, California

United States, Florida

United States, Louisiana

United States, Michigan

United States, Ohio

United States, Tennessee

United States, Texas

Europe

France

Italy